# OnCo record nct07106762 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07106762/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07106762", "NCT07106762" ;
  schema:name "Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy"@en ;
  schema:alternateName "IZABRIGHT-Bladder01"@en ;
  schema:description "A phase 2/3 trial of Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by Bristol-Myers Squibb, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07106762/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07106762> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2025-09-30" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/muscle-invasive-bladder-cancer/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/bms/> .